Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Thursday. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Price Performance

Shares of CTSO opened at $0.89 on Thursday. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $2.15. The business’s 50 day moving average price is $0.98 and its two-hundred day moving average price is $1.01. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Institutional Trading of Cytosorbents

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sargent Investment Group LLC grew its holdings in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares during the last quarter. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the 3rd quarter valued at about $51,000. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, CM Management LLC raised its stake in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.